TD2 - About the company
TD2 is an acquired company based in Phoenix (United States), founded in 2003. It operates as an Oncology CRO accelerating cancer drug development with integrated preclinical and clinical services. The company has 2002 active competitors, including 454 funded and 326 that have exited. Its top competitors include companies like Crown Bioscience, Antheia and Transcenta.
Company Details
Oncology CRO accelerating cancer drug development with integrated preclinical and clinical services. The company is dedicated to advancing oncology drug development through precision, expertise, and efficiency. It offers strategic solutions to accelerate the path from scientific discoveries to patient therapies. The company's ecosystem connects preclinical, clinical, and regulatory phases, prioritizing scientific innovation and patient outcomes. Services include study design, patient identification, site management, biostatistics, data management, pharmacovigilance, and medical monitoring. It also provides regulatory support, including program management, protocol design, and submission filings. Preclinical services encompass model systems, bioanalytical services, and in vivo/in vitro characterization. Flow cytometry services offer analysis for preclinical and clinical studies. The company fosters collaboration, ensuring clear communication and tailored guidance. Its multidisciplinary team brings insights into oncology development, supporting programs across diverse therapeutic modalities like targeted therapies, immuno-oncology, antibody-drug conjugates, and radiopharmaceuticals.
- Website
- td2inc.com
- Registered Address
- Scottsdale, Arizona
Key Metrics
Founded Year
2003
Location
Phoenix, United States
Stage
Acquired
Ranked
471st among 2002 active competitors
Employee Count
120 as on Aug 31, 2026
Exit Details
Acquired by RCT (Jun 04, 2020)
Legal entities associated with TD2
TD2 is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Translational Drug Development, Llc CIN: 464150915 , United States, Active | Dec 26, 999 | - | 167 (As on Dec 31, 2024) | - |
TD2's acquisition details
TD2 got acquired by RCT on Jun 04, 2020.
Click here to take a look at TD2's acquisition in detail
Sign up to download TD2's company profile
TD2's funding and investors
TD2 has not raised any funding rounds yet.
TD2's founders and board of directors
Founder? Claim ProfileTD2's employee count trend
TD2 has 120 employees as of Aug 26. Here is TD2's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
TD2's Competitors and alternates
Top competitors of TD2 include Crown Bioscience, Antheia and Transcenta. Here is the list of Top 10 competitors of TD2, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Crown Bioscience 2006, Santa Clara (United States), Acquired | Developer of drugs for cancer and CVMD (Cardiovascular and Metabolic Diseases) | $85.9M | 68/100 | |
2nd | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
3rd | Transcenta 2019, Suzhou (China), Public | Developer of antibody-based therapeutics | $205M | 66/100 | |
4th | Developer of antibody drug conjugates for the treatment of broad spectrum diseases | $195M | 65/100 | ||
5th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 64/100 | |
6th | Fermentalg 2005, Libourne (France), Public | Innovating with algae for sustainable solutions in nutrition and environmental impact | $30.3M | 63/100 | |
7th | Microban 1994, Huntersville (United States), Acquired | Antimicrobial and odor control technologies for durable product protection and freshness | $64.6M | 63/100 | |
8th | LifeMine Therapeutics 2016, Watertown (United States), Series E | Developer of novel drugs from fungi via genome mining and recombinant overexpression | $563M | 63/100 | |
9th | Dewpoint Therapeutics 2018, Boston (United States), Series D | Developer of small molecule based therapeutics | $364M | 62/100 | |
10th | One Biosciences 2020, Paris (France), Series A | Developer of single-cell therapeutics solutions to treat multiple health disorders | $22.4M | 62/100 | |
471st | TD2 2003, Phoenix (United States), Acquired | Oncology CRO accelerating cancer drug development with integrated preclinical and clinical services | - | - | 34/100 |
Looking for more details on TD2's competitors? Click here to see the top ones
TD2's Investments and acquisitions
TD2 has made no investments or acquisitions yet.
Reports related to TD2
Here is the latest report on TD2's sector:
News related to TD2
•
Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302GlobeNewswire•Mar 30, 2022•Qualigen, TD2
•
•
•
•
TD2 and Deep 6 AI Announce Partnership to Accelerate Oncology Clinical Trial RecruitmentBusiness Wire•May 31, 2017•TD2, Deep 6 AI
Are you a Founder ?
FAQs about TD2
Explore our recently published companies
- Solar - Indore based, 1994 founded, Unfunded company
- Bina Punjani - India based, 2011 founded, Unfunded company
- Aviator - India based, Unfunded company
- Admit Beacon - India based, 2021 founded, Unfunded company
- Origin Itfs - Chennai based, 1993 founded, Unfunded company
- 1Win - India based, 2026 founded, Unfunded company